Baxter Third Quarter Results On Track to Meet Full Year Guidance
Baxter reported third-quarter results that put it on track to meet our $4.68 adjusted EPS estimate for the year, slightly ahead of management guidance of $4.65-$4.67. We’re maintaining our $80 fair value estimate despite branded hemophilia and generic anesthesia and chemotherapy competition that will likely begin to emerge as headwinds in early 2014. We think…
